Literature DB >> 18584926

Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: quantitative and qualitative effects of CD4+ T cells.

Eun-Kyung Kim1, Hyun-Il Cho, Sung Hee Yoon, Min-Ji Park, Hyun-Jung Sohn, Hyung-Jin Kim, Seong-Taek Oh, Tai-Gyu Kim.   

Abstract

For the adoptive immunotherapy and the study of cytotoxic T lymphocytes (CTLs) in human, efficient in vitro generation of CTLs is needed. However, it is still difficult to induce T cells specific for naïve antigens in vitro even though dendritic cells (DCs) as potent APCs are used. In this study, we investigated quantitative and qualitative effects of CD4+ T cells during in vitro stimulation of CD8+ T cells from healthy donors using DCs transduced with adenovirus vector expressing human survivin (Adv-survivin). CTLs were not efficiently induced in the absence of CD4+ T cells or in CD25+ depleted CD4+ T cells. When the ratio of CD4+:CD8+ T cells was quantitatively decreased from 2:1 to 1:2, proliferation of CTLs specific for survivin was gradually increased. Because DCs pulsed with HCMV pp65 protein could activate CD4+ T cells to secrete Th1 cytokines, the use of pp65 protein as an adjuvant induced higher numbers and frequencies of CTLs. Furthermore, Th1 conditioning of CD4+ T cells augmented this generation of CTLs. These results suggest that both quantitative and qualitative modulation of CD4+ T cells including the number and Th1 polarization may be required for the efficient induction of CTLs specific for tumor antigens in vitro.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584926     DOI: 10.1016/j.vaccine.2008.05.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma.

Authors:  Robert A Fenstermaker; Michael J Ciesielski; Jingxin Qiu; Nuo Yang; Cheryl L Frank; Kelvin P Lee; Laszlo R Mechtler; Ahmed Belal; Manmeet S Ahluwalia; Alan D Hutson
Journal:  Cancer Immunol Immunother       Date:  2016-08-30       Impact factor: 6.968

2.  Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.

Authors:  Bently P Doonan; Azizul Haque
Journal:  J Clin Cell Immunol       Date:  2015-08-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.